272 related articles for article (PubMed ID: 25913920)
1. Role of the Pharmacist in Medication Therapy Management Services in Patients With Osteoporosis.
Murphy-Menezes M
Clin Ther; 2015 Jul; 37(7):1573-86. PubMed ID: 25913920
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
[TBL] [Abstract][Full Text] [Related]
3. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
Nayak S; Greenspan SL
Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
[TBL] [Abstract][Full Text] [Related]
5. Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication.
Stuurman-Bieze AG; Hiddink EG; van Boven JF; Vegter S
Osteoporos Int; 2014 Jun; 25(6):1807-12. PubMed ID: 24570297
[TBL] [Abstract][Full Text] [Related]
6. Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.
Yun H; Curtis JR; Guo L; Kilgore M; Muntner P; Saag K; Matthews R; Morrisey M; Wright NC; Becker DJ; Delzell E
BMC Musculoskelet Disord; 2014 Apr; 15():112. PubMed ID: 24684864
[TBL] [Abstract][Full Text] [Related]
7. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
8. Long-term persistence with anti-osteoporosis drugs after fracture.
Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
[TBL] [Abstract][Full Text] [Related]
9. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
McClung M
Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
[TBL] [Abstract][Full Text] [Related]
10. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
[TBL] [Abstract][Full Text] [Related]
11. Retained Skeletal Effects of Zoledronic Acid Following Discontinuation of Treatment: A Review of the Literature.
Deas CM; Murphy P; Iranikhah M; Freeman MK
Consult Pharm; 2017 Mar; 32(3):144-155. PubMed ID: 28270269
[TBL] [Abstract][Full Text] [Related]
12. Atypical femur fracture during bisphosphonate drug holiday: a case series.
Lovy AJ; Koehler SM; Keswani A; Joseph D; Hasija R; Ghillani R
Osteoporos Int; 2015 Jun; 26(6):1755-8. PubMed ID: 25832177
[TBL] [Abstract][Full Text] [Related]
13. Impact of interactive voice response technology on primary adherence to bisphosphonate therapy: a randomized controlled trial.
Cizmic AD; Heilmann RM; Milchak JL; Riggs CS; Billups SJ
Osteoporos Int; 2015 Aug; 26(8):2131-6. PubMed ID: 25956282
[TBL] [Abstract][Full Text] [Related]
14. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.
Curtis JR; Westfall AO; Cheng H; Delzell E; Saag KG
Osteoporos Int; 2008 Nov; 19(11):1613-20. PubMed ID: 18483689
[TBL] [Abstract][Full Text] [Related]
15. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
[TBL] [Abstract][Full Text] [Related]
16. Oral bisphosphonate compliance and persistence: a matter of choice?
Silverman SL; Schousboe JT; Gold DT
Osteoporos Int; 2011 Jan; 22(1):21-6. PubMed ID: 20458571
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a Nationwide Pharmacist-Led Phone Outreach Program to Improve Osteoporosis Management in Older Women with Recently Sustained Fractures.
Tso LS; Loi D; Mosley DG; Yi D; Stockl KM; Lew HC; Solow BK
J Manag Care Spec Pharm; 2015 Sep; 21(9):803-10. PubMed ID: 26308227
[TBL] [Abstract][Full Text] [Related]
18. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
[TBL] [Abstract][Full Text] [Related]
19. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
Gold DT; Alexander IM; Ettinger MP
Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
[TBL] [Abstract][Full Text] [Related]
20. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
Ganda K; Schaffer A; Pearson S; Seibel MJ
Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
